论文部分内容阅读
目的探讨强直性脊柱炎(AS)患者血清高迁移率族蛋白B1(HMGB1)和肿瘤坏死因子α(TNFα)的表达及其与疾病活动的相关性,以寻找治疗AS新靶点。方法本研究纳入50名AS患者,其中30例为初诊未治疗活动期患者,20例为治疗三个月稳定期患者。从同地区选取性别、年龄和种族与疾病组配对的30名正常志愿者作为健康对照。通过ELISA方法测定不同组别的血清HMGB1与TNFα的表达,检测治疗前后与对照组血清HMGB1与TNFα的表达水平,比较分析AS患者HMGB1与TNFα变化以及其与炎性指标、AS躯体功能指数BASFI和AS活动性指数BASDAI之间的相关性。结果 AS患者血清中HMGB1和TNFα水平明显高于正常组,稳定期较活动期患者二者水平明显下降,但仍高于健康对照组;AS患者血清中HMGB1和TNF-α水平均与血沉、超敏C反应蛋白(hsCRP)、BASFI、BASDAI呈正相关;AS患者血清中HMGB1和TNFα水平呈明显的正相关。结论 AS中HMGB1与TNFα的表达升高,与疾病活动性正相关,且两种因子有较强的正相关性,HMGB1在AS的发病中可能扮演了重要角色。
Objective To investigate the expression of serum high mobility group box-1 (HMGB1) and tumor necrosis factor-α (TNFα) in patients with ankylosing spondylitis (AS) and its relationship with disease activity in order to find a new therapeutic target for AS. Methods Fifty AS patients were enrolled in this study. Thirty of them were newly diagnosed untreated patients and 20 were treated for stable patients for three months. Thirty normal volunteers who were matched by gender, age and ethnicity and disease group in the same region were selected as healthy controls. The serum levels of HMGB1 and TNFα were measured by ELISA. The serum levels of HMGB1 and TNFα were measured before and after treatment. The changes of HMGB1 and TNFα in AS patients were compared with those of inflammatory markers, ASFI and BASFI AS Activity Index BASDAI correlation between. Results The serum levels of HMGB1 and TNFα in patients with AS were significantly higher than those in normal controls, while those in patients with stable activity were significantly lower than those in healthy controls (P <0.05). However, the serum levels of HMGB1 and TNF- Serum C-reactive protein (hsCRP), BASFI and BASDAI were positively correlated. Serum levels of HMGB1 and TNFα in patients with AS were positively correlated. Conclusions The expression of HMGB1 and TNFα in AS is increased, positively correlated with disease activity, and the two factors have a strong positive correlation. HMGB1 may play an important role in the pathogenesis of AS.